Drug Database
RO

ropinirole (Requip CR / ropinirole 24hr / Requip LP)

✓ Approved

SkyePharma PLC · DRD2 · 小分子

什么是 ropinirole?

ropinirole 是一种小分子,由SkyePharma PLC研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Requip CR, ropinirole 24hr, Requip LP
公司SkyePharma PLC
药物类别小分子
分子靶点DRD2, DRD3
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

ropinirole 作用于 2 个分子靶点:

DRD2dopamine receptor D2 (D2DR, D2R)
DRD3dopamine receptor D3 (D3DR, FET1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

ropinirole 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersParkinson's disease✓ Approved
Nervous system disordersRestless legs syndromePhase II

相关研究文献

PubMedLife sciences2026-11-17

Neuroprotective effects of ropinirole against nicotine- and ethanol-induced cognitive impairment, oxidative stress, neuroinflammation, and neurodegenerative alterations in rats.

Azizi Omid O, Ghasemi Reza R, Kakhki Samaneh S, Etebari Maryam M et al.

Adolescence is a critical period of brain development during which exposure to addictive substances may adversely affect cognitive function and neuronal plasticity. Combined nicotine and ethanol exposure may contribute to persistent cognitive impairment through disturbances in oxidative balance, inflammatory signaling, and hippocampal function. However, the potential effects of pharmacological interventions targeting these alterations after exposure remain insufficiently characterized. Given the previously reported neuroprotective properties of ropinirole, this study investigated whether post-exposure treatment with this dopamine D2/D3 receptor agonist could attenuate cognitive deficits and associated hippocampal biochemical alterations in rats subjected to adolescent nicotine-ethanol co-exposure. Male Wistar rats were exposed to nicotine (2 mg/kg/day, intraperitoneally) and ethanol (20% v/v in drinking water) during adolescence (postnatal days 21-48). Following the exposure period, animals received oral ropinirole at doses of 5, 10, or 20 mg/kg/day for three weeks. Spatial learning and memory and recognition memory were assessed using the Morris water maze and novel object recognition tests, respectively. Hippocampal biochemical assessments included malondialdehyde (MDA), nitrite, total thiol content, superoxide dismutase (SOD), catalase, tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), brain-derived neurotrophic factor (BDNF), acetylcholinesterase (AChE), and amyloid-β (Aβ). Nicotine-ethanol co-exposure significantly impaired spatial learning, memory retention, and recognition memory, accompanied by increased hippocampal MDA, nitrite, TNF-α, AChE activity, and Aβ levels, together with reduced antioxidant capacity, IL-10, and BDNF expression. Post-exposure ropinirole treatment improved performance in the behavioral tests and attenuated several of the associated biochemical alterations. The 20 mg/kg dose generally showed the most pronounced effects among the doses tested; however, a formal dose-response relationship was not established. These findings suggest that ropinirole exerts neuroprotective effects against adolescent nicotine-ethanol-induced cognitive impairment through the modulation of oxidative stress, neuroinflammation, cholinergic dysfunction, neurotrophic signaling, and amyloid-related pathways. These results provide preliminary evidence supporting dopaminergic modulation as a potential strategy for mitigating substance-associated cognitive dysfunction, although further mechanistic and translational studies are necessary.

PMID 43045009
阅读全文 →
PubMedRinsho shinkeigaku = Clinical neurology2026-11-16

Cholesterol dysmetabolism in motor neurons drives ALS pathogenesis.

Morimoto Satoru S, Takahashi Shinichi S, Okano Hideyuki H

In amyotrophic lateral sclerosis (ALS), cholesterol dysmetabolism in motor neurons has emerged as a central pathogenic axis. Oxysterols generated under oxidative stress exert potent lower motor neuron toxicity via lysosomal and mitochondrial dysfunction and by triggering oxiapoptophagy, a form of cell death in which oxidative stress, apoptosis, and autophagy co-occur. Moreover, TAR DNA-binding protein 43 (TDP-43) dysfunction and pathogenic variants in ALS-related genes including C9orf72, VAPB, and SIGMAR1 can amplify lipid toxicity through impaired function of mitochondria-associated endoplasmic reticulum membranes (MAMs) and defective intracellular cholesterol trafficking. Genome-wide association studies (GWAS) and Mendelian randomization (MR) analyses indicate that genetically predicted elevations in low-density lipoprotein cholesterol (LDL-C), total cholesterol, and apolipoprotein B (ApoB) are associated with increased ALS risk, whereas the effects of statins appear heterogeneous and context-dependent, varying by agent, dose, and treatment duration. In drug discovery using patient-derived induced pluripotent stem cell (iPSC)-derived lower motor neurons (iPSC-LMNs), ropinirole hydrochloride suppresses the expression of enzymes involved in de novo cholesterol synthesis while reducing reactive oxygen species, inhibiting aggregation of TDP-43 and fused in sarcoma (FUS), and improving mitochondrial function; importantly, in vitro responsiveness correlates with clinical efficacy. Furthermore, integrating a polygenic risk score (PRS) for total cholesterol with iPSC-LMN phenotypes has been proposed as a stratification strategy to define an ALS subtype driven by hyperactive cholesterol metabolism and to identify patients more likely to benefit from cholesterol biosynthesis-suppressing therapies. Collectively, candidate disease-modifying interventions targeting cholesterol dysmetabolism are increasingly positioned as a promising translational research axis in ALS.

PMID 43035909
阅读全文 →
PubMedStem cells (Dayton, Ohio)2026-11-13

iPSC-based Approaches to Amyotrophic Lateral Sclerosis: from Drug Screening to Regenerative Medicine in Early Clinical Translation.

Lu Jessica Jianghan JJ, Cheung Martin M

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterised by progressive loss of upper and lower motor neurons (MNs), with limited therapeutic options and modest benefit from currently approved drugs. Induced pluripotent stem cells (iPSCs) have emerged as a versatile platform for ALS research, enabling both regenerative medicine and phenotypic drug screening. iPSC-based transplantation strategies aim to replace lost cells or deliver neuroprotective support, while iPSC-derived MNs support drug discovery and repositioning. In the two decades since their discovery, iPSC technologies have progressed from concept to clinical translation, with both cell therapy products such as AstroRx and XS-228 entering trials and three screened drug candidates, Ropinirole, Bosutinib, and Ezogabine, advancing into clinical trials, underscoring their translational potential. In this review, we summarise iPSC-based approaches to ALS, focusing on cell therapies and drug discovery, highlight factors influencing transplantation success, and discuss ongoing clinical trials. We further discuss constraints that impede clinical trial progress, including limited understanding of ALS pathogenesis, absence of robust biomarkers to guide patient stratification and evaluate treatment response, and technical challenges related to the maturation of iPSC-derived neural cells. Finally, we advocate that advancing iPSC approaches requires both deeper understanding of ALS biology and technical innovation. Key priorities are refining iPSC differentiation protocols to improve neuronal maturity and implementing trial designs with adequate duration and rigorous patient stratification.

PMID 43023417
阅读全文 →
PubMedPsychopharmacology bulletin2026-11-04

Psychiatric and Behavioral Adverse Event Reporting Patterns Among Dopamine Agonists in Parkinson's Disease Using the Food and Drug Administration Adverse Event Reporting System.

Ogura Toru T, Shiraishi Chihiro C

Dopamine agonists used in Parkinson's disease are associated with neuropsychiatric and behavioral adverse events (AEs), including hallucinations and impulse control disorders. This study aimed to compare AE reporting patterns among pramipexole, ropinirole, and rotigotine in the Food and Drug Administration Adverse Event Reporting System (FAERS) and to identify drug-specific pharmacovigilance signals. This retrospective study analyzed FAERS data using disproportionality analysis. Reporting odds ratios (RORs) and adjusted RORs (aRORs) were calculated with pramipexole as the reference drug; ropinirole and rotigotine were each compared with pramipexole. A Bonferroni-corrected significance threshold of P < 0.025 was used for the two pairwise comparisons. We analyzed 5,959 cases (pramipexole N = 1,654; ropinirole N = 1,450; rotigotine N = 2,855). Compared with pramipexole, ropinirole was associated with significantly higher reporting of gastrointestinal disorders and lower reporting of impulse control disorders. Rotigotine was associated with lower reporting of neuropsychiatric disorders (excluding impulse control disorders), impulse control disorders, and general and systemic disorders, but higher reporting of dermatological and application-site disorders, infectious disorders, and serious outcome-related events. Dopamine agonists showed distinct AE reporting profiles in FAERS, particularly for neuropsychiatric, impulse-control, and other regimen-related events. These findings are pharmacovigilance signals rather than causal associations, but they may help inform psychiatric risk assessment and individualized dopamine agonist selection. Confirmation in prospective clinical or pharmacoepidemiological studies is warranted.

PMID 42979628
阅读全文 →
PubMedThe Cochrane database of systematic reviews2026-10-29

Levodopa or dopamine agonists for enhancing motor function after stroke.

Jauslin Andrea S AS, Boos Lukas L, Hirt Julian J, Altersberger Valerian V et al.

Stroke is a leading cause of mortality and disability worldwide. There is a lack of evidence regarding pharmacological enhancement of stroke recovery with dopamine agonists or levodopa, in particular in terms of motor deficits. To assess the effects of dopaminergic agents, defined as levodopa or dopamine agonists, on improving motor function after stroke. We conducted an extensive database search on the Cochrane Stroke Group trials register, CENTRAL, MEDLINE, Embase, CINAHL, PsycINFO, Science Citation Index Expanded, CPCI-S, BIOSIS Citation Index, ProQuest Dissertation and Theses Global up to November 2025. We included randomised controlled trials (RCTs) that enrolled participants with a clinical diagnosis of stroke, irrespective of age or stroke aetiology and without a pre-existing indication for the use of levodopa or dopamine agonists. Eligible trials compared levodopa or dopamine agonists with a comparator group who received placebo or no medication, with equivalent rehabilitative care in both groups, and aimed at enhancing motor function after stroke. Motor function was the critical benefit outcome. As a critical harm outcome, we assessed serious adverse events. Important outcomes consisted of death, recurrent stroke, disability, dependence, health-related quality of life, activities of daily living, total number of adverse events, and psychiatric adverse events. Two review authors independently assessed the risk of bias for each trial using the Cochrane Risk of bias tool (RoB 1). We synthesised results for each outcome using a standardised mean difference (SMD) or mean difference (MD) for continuous data and risk ratio (RR) for dichotomous results, with a random-effects model due to heterogeneity between the trials. For non-extractable trials due to missing numerical data, we synthesised the results narratively. We used GRADE to assess the certainty of evidence for each outcome. We included 12 parallel-group RCTs involving 1860 participants. The trials were conducted in Europe, the USA and Asia, and were published between 2001 and 2025. All trials included participants with either ischaemic strokes only or both haemorrhagic and ischaemic strokes. The mean age of all included participants ranged from 55 to 78 years. Of the included trials, 10 were placebo-controlled and two compared levodopa or dopamine agonists against usual care. Eleven trials investigated levodopa as the intervention and one examined the dopamine agonist ropinirole. Across 12 included trials, complete data on motor function were available for six trials with continuous data (1258 participants) and for two trials with dichotomous data (615 participants), of which one trial assessed both continuous and dichotomous data. We detected no difference in motor function scores between levodopa or dopamine agonists and the comparator groups for continuous outcomes (SMD 1.42, 95% confidence interval (CI) -0.20 to 3.05; 6 trials, 1258 participants; very low-certainty evidence). The wide confidence intervals indicate substantial imprecision in the effect estimate. Consistent with those results, we detected no difference for dichotomous motor function outcomes either (RR 0.93, 95% CI 0.82 to 1.06; 2 trials, 615 participants; anticipated absolute event rate of having a favourable outcome of 581/1000 in the comparator group versus 540/1000 with levodopa/dopamine agonists; low-certainty evidence). Heterogeneity for the critical outcome motor function (continuously measured) was high (I2 = 99%). However, a sensitivity analysis including only two trials with a low risk of bias in all domains, that accounted for the majority of the included patient population (1025 of 1258), showed no heterogeneity (I2 = 0%), and a smaller confidence interval (SMD 0.02, 95% CI -0.10 to 0.14; 2 trials, 1025 participants), implying no difference between groups. Six trials assessed serious adverse events, including 1281 participants. There was no notable difference in the risk of serious adverse events between groups (RR 1.03, 95% CI 0.83 to 1.27; anticipated absolute event rate of 302/1000 events in comparators versus 311/1000 events with levodopa/dopamine agonists; low-certainty evidence). All important outcomes showed no notable between-group differences. The certainty of evidence, according to GRADE, was very low for continuously measured scores of motor function, low for dichotomous motor function outcomes, and low for serious adverse events. Together with heterogeneity in both interventions and outcomes, inconsistency of findings, imprecision related to small sample sizes in some trials, and imprecision of summary effect, there are major limitations of the current evidence. Based on limited data, we did not find evidence that the use of levodopa or dopamine agonists improves motor function after a stroke. Given the low certainty of evidence due to limited data, wide confidence intervals, and heterogeneity across trials, further research may change this assessment and explore whether effects are different in specific subgroups of patients. Science funds [Wissenschaftsfonds] Department of Rehabilitation and Neurology, University Department of Geriatric Medicine, Felix Platter, University of Basel, Switzerland. This review had no external funding. Protocol available via https://doi.org/10.1002/14651858.CD013416.

PMID 42954433
阅读全文 →
PubMedBiological & pharmaceutical bulletin2026-10-25

Interleukin-31 Induces Itch-Related Responses with Precursor Behaviors in Mice and Its Suppression by the Dopamine D2/D3 Receptor Agonist Ropinirole.

Andoh Tsugunobu T, Suzuki Mami M

Recent research has revealed that human itch manifests in a variety of distinct phenotypes, such as muzumuzu (creepy-crawly itch, a bit like tickling). We have also demonstrated that scratching behaviors induced by pruritogens in mice are sometimes preceded by specific precursor behaviors, such as shivering or forelimb grooming, whereas in other cases, these precursors are absent. These findings suggest that mice, like humans, exhibit characteristic itch-related behaviors. In the present study, we focused on interleukin-31 (IL-31), which has been implicated in atopic dermatitis-associated itch, and investigated whether precursor behaviors were observed during IL-31-induced itch-related behaviors in mice. Male ICR mice were used in this study. Following intradermal injection of IL-31, subsequent behaviors were recorded with a digital video camera, and scratch behaviors were counted based on the presence or absence of precursor behaviors. Intradermal IL-31-induced scratching with precursor behaviors was significantly higher than that without them. Dopamine D2 receptor agonists are reported to be effective against restless sensations. Ropinirole, a dopamine D2/D3 receptor agonist, significantly suppressed IL-31-induced scratching with precursor behaviors. Interestingly, ropinirole also attenuated IL-31-induced scratching without precursor behaviors. Histamine induces scratching that is unaccompanied by precursor behaviors compared to those accompanied by them. Ropinirole also inhibited histamine-induced scratching, both with and without precursor behaviors. In conclusion, these findings provide the first evidence that IL-31-induced itch-related responses are primarily characterized by precursor behaviors. Moreover, the fact that ropinirole significantly suppressed both IL-31- and histamine-induced scratching suggests that ropinirole holds therapeutic promise for managing diverse itch signaling pathways.

PMID 42927937
阅读全文 →

注册免费账户还可查看另外 968 篇文献

免费注册查看全部文献 →

了解更多ropinirole